Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Jul;70(7):4361–4369. doi: 10.1128/jvi.70.7.4361-4369.1996

Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.

R Shibata 1, C Siemon 1, M W Cho 1, L O Arthur 1, S M Nigida Jr 1, T Matthews 1, L A Sawyer 1, A Schultz 1, K K Murthy 1, Z Israel 1, A Javadian 1, P Frost 1, R C Kennedy 1, H C Lane 1, M A Martin 1
PMCID: PMC190369  PMID: 8676459

Abstract

To test whether the protective effects of attenuated simian immunodeficiency virus vaccines in macaques were applicable to the human immunodeficiency virus type 1 (HIV-1)-chimpanzee system, two groups of animals, previously infected with HIV-1(IIIB) or HIV-1(SF2) were each challenged with a heterologous clade B virus, HIV-1(DH12). Following challenge, the parameters measured included virus isolation (from plasma, peripheral blood mononuclear cells, and lymph node tissue); quantitative DNA PCR using primers capable of distinguishing HIV-1(IIIB), HIV-1(SF2), and HIV-1(DH12) from one another; and serologic assays to monitor changes in binding and neutralizing antibodies. In contrast to an HIV-1-naive chimpanzee that rapidly became infected following the inoculation of HIV-1(DH12), the two chimpanzees previously infected with HIV-1(IIIB) resisted repeated and escalating inoculations of HIV-1(DH12), as monitored by virus isolation and PCR. The two animals previously infected with HIV-1(SF2) became infected with HIV-1(DH12) but in contrast to the case with the HIV-1-naive chimpanzee, no cell-free viral RNA was detected in the plasma by the branched DNA procedure and levels of peripheral blood mononuclear cell-associated viral DNA were reduced 35- to 50-fold.

Full Text

The Full Text of this article is available as a PDF (379.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almond N., Kent K., Cranage M., Rud E., Clarke B., Stott E. J. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet. 1995 May 27;345(8961):1342–1344. doi: 10.1016/s0140-6736(95)92540-6. [DOI] [PubMed] [Google Scholar]
  2. Arthur L. O., Bess J. W., Jr, Waters D. J., Pyle S. W., Kelliher J. C., Nara P. L., Krohn K., Robey W. G., Langlois A. J., Gallo R. C. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol. 1989 Dec;63(12):5046–5053. doi: 10.1128/jvi.63.12.5046-5053.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Belshe R. B., Graham B. S., Keefer M. C., Gorse G. J., Wright P., Dolin R., Matthews T., Weinhold K., Bolognesi D. P., Sposto R. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA. 1994 Aug 10;272(6):475–480. doi: 10.1001/jama.272.6.475. [DOI] [PubMed] [Google Scholar]
  4. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990 Jun 14;345(6276):622–625. doi: 10.1038/345622a0. [DOI] [PubMed] [Google Scholar]
  5. Berman P. W., Groopman J. E., Gregory T., Clapham P. R., Weiss R. A., Ferriani R., Riddle L., Shimasaki C., Lucas C., Lasky L. A. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5200–5204. doi: 10.1073/pnas.85.14.5200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bruck C., Thiriart C., Fabry L., Francotte M., Pala P., Van Opstal O., Culp J., Rosenberg M., De Wilde M., Heidt P. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine. 1994 Sep;12(12):1141–1148. doi: 10.1016/0264-410x(94)90185-6. [DOI] [PubMed] [Google Scholar]
  7. Clements J. E., Montelaro R. C., Zink M. C., Amedee A. M., Miller S., Trichel A. M., Jagerski B., Hauer D., Martin L. N., Bohm R. P. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol. 1995 May;69(5):2737–2744. doi: 10.1128/jvi.69.5.2737-2744.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. doi: 10.1126/science.1470917. [DOI] [PubMed] [Google Scholar]
  9. Dewar R. L., Highbarger H. C., Sarmiento M. D., Todd J. A., Vasudevachari M. B., Davey R. T., Jr, Kovacs J. A., Salzman N. P., Lane H. C., Urdea M. S. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis. 1994 Nov;170(5):1172–1179. doi: 10.1093/infdis/170.5.1172. [DOI] [PubMed] [Google Scholar]
  10. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. doi: 10.1038/355728a0. [DOI] [PubMed] [Google Scholar]
  11. Emini E. A., Schleif W. A., Quintero J. C., Conard P. G., Eichberg J. W., Vlasuk G. P., Lehman E. D., Polokoff M. A., Schaeffer T. F., Schultz L. D. Yeast-expressed p55 precursor core protein of human immunodeficiency virus type 1 does not elicit protective immunity in chimpanzees. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1247–1250. doi: 10.1089/aid.1990.6.1247. [DOI] [PubMed] [Google Scholar]
  12. Fultz P. N., Nara P., Barre-Sinoussi F., Chaput A., Greenberg M. L., Muchmore E., Kieny M. P., Girard M. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science. 1992 Jun 19;256(5064):1687–1690. doi: 10.1126/science.256.5064.1687. [DOI] [PubMed] [Google Scholar]
  13. Fultz P. N., Srinivasan A., Greene C. R., Butler D., Swenson R. B., McClure H. M. Superinfection of a chimpanzee with a second strain of human immunodeficiency virus. J Virol. 1987 Dec;61(12):4026–4029. doi: 10.1128/jvi.61.12.4026-4029.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gibbs C. J., Jr, Peters R., Gravell M., Johnson B. K., Jensen F. C., Carlo D. J., Salk J. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3348–3352. doi: 10.1073/pnas.88.8.3348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Girard M., Kieny M. P., Pinter A., Barre-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):542–546. doi: 10.1073/pnas.88.2.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Girard M., Meignier B., Barré-Sinoussi F., Kieny M. P., Matthews T., Muchmore E., Nara P. L., Wei Q., Rimsky L., Weinhold K. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol. 1995 Oct;69(10):6239–6248. doi: 10.1128/jvi.69.10.6239-6248.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Graham B. S., Matthews T. J., Belshe R. B., Clements M. L., Dolin R., Wright P. F., Gorse G. J., Schwartz D. H., Keefer M. C., Bolognesi D. P. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis. 1993 Mar;167(3):533–537. doi: 10.1093/infdis/167.3.533. [DOI] [PubMed] [Google Scholar]
  18. Harada S., Koyanagi Y., Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985 Aug 9;229(4713):563–566. doi: 10.1126/science.2992081. [DOI] [PubMed] [Google Scholar]
  19. Heeney J. L., Holterman L., ten Haaft P., Dubbes R., Koornstra W., Teeuwsen V., Bourquin P., Norley S., Niphuis H. Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. AIDS Res Hum Retroviruses. 1994;10 (Suppl 2):S117–S121. [PubMed] [Google Scholar]
  20. Hu S. L., Fultz P. N., McClure H. M., Eichberg J. W., Thomas E. K., Zarling J., Singhal M. C., Kosowski S. G., Swenson R. B., Anderson D. C. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature. 1987 Aug 20;328(6132):721–723. doi: 10.1038/328721a0. [DOI] [PubMed] [Google Scholar]
  21. Levy J. A., Hoffman A. D., Kramer S. M., Landis J. A., Shimabukuro J. M., Oshiro L. S. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984 Aug 24;225(4664):840–842. doi: 10.1126/science.6206563. [DOI] [PubMed] [Google Scholar]
  22. Lohman B. L., McChesney M. B., Miller C. J., McGowan E., Joye S. M., Van Rompay K. K., Reay E., Antipa L., Pedersen N. C., Marthas M. L. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol. 1994 Nov;68(11):7021–7029. doi: 10.1128/jvi.68.11.7021-7029.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Marthas M. L., Sutjipto S., Higgins J., Lohman B., Torten J., Luciw P. A., Marx P. A., Pedersen N. C. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol. 1990 Aug;64(8):3694–3700. doi: 10.1128/jvi.64.8.3694-3700.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pantaleo G., Graziosi C., Butini L., Pizzo P. A., Schnittman S. M., Kotler D. P., Fauci A. S. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9838–9842. doi: 10.1073/pnas.88.21.9838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Popovic M., Sarngadharan M. G., Read E., Gallo R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984 May 4;224(4648):497–500. doi: 10.1126/science.6200935. [DOI] [PubMed] [Google Scholar]
  26. Prince A. M., Horowitz B., Baker L., Shulman R. W., Ralph H., Valinsky J., Cundell A., Brotman B., Boehle W., Rey F. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6944–6948. doi: 10.1073/pnas.85.18.6944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Prince A. M., Reesink H., Pascual D., Horowitz B., Hewlett I., Murthy K. K., Cobb K. E., Eichberg J. W. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses. 1991 Dec;7(12):971–973. doi: 10.1089/aid.1991.7.971. [DOI] [PubMed] [Google Scholar]
  28. Putkonen P., Thorstensson R., Albert J., Hild K., Norrby E., Biberfeld P., Biberfeld G. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS. 1990 Aug;4(8):783–789. doi: 10.1097/00002030-199008000-00010. [DOI] [PubMed] [Google Scholar]
  29. Saksela K., Muchmore E., Girard M., Fultz P., Baltimore D. High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol. 1993 Dec;67(12):7423–7427. doi: 10.1128/jvi.67.12.7423-7427.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Shibata R., Hoggan M. D., Broscius C., Englund G., Theodore T. S., Buckler-White A., Arthur L. O., Israel Z., Schultz A., Lane H. C. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J Virol. 1995 Jul;69(7):4453–4462. doi: 10.1128/jvi.69.7.4453-4462.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Walker C. M., Moody D. J., Stites D. P., Levy J. A. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986 Dec 19;234(4783):1563–1566. doi: 10.1126/science.2431484. [DOI] [PubMed] [Google Scholar]
  32. Willey R. L., Smith D. H., Lasky L. A., Theodore T. S., Earl P. L., Moss B., Capon D. J., Martin M. A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol. 1988 Jan;62(1):139–147. doi: 10.1128/jvi.62.1.139-147.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES